Axogen reports preliminary Q4 2022 revenue of $36.1M, up 16% YoY ex-Avive; FY22 $138.5M, up 12%

Axogen, Inc.

2022-FY EPS reported -$0.69 revenue$138,584,000

Q4 revenue $36.1M, up 14% reported or 16% excluding Avive; FY22 $138.5M, up 9% reported or 12% ex-Avive.
Cash and investments ~$55.0M at Dec 31, down from $59.4M at Sep 30; includes $5.3M capex for new Dayton, OH facility.
115 direct sales reps (flat YoY); 332 Core Accounts (+1% sequential); 968 Active Accounts (+2% sequential).
Surpassed 75,000 Avance Nerve Graft implants since launch; BLA submission planned for H2 2023.
Reaffirms FY22 gross margin above 80%; full FY23 outlook to be provided on March 14, 2023 earnings call.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Axogen, Inc. reported fourth quarter and full-year 2022 results: revenue approximately $36.1 million, a 16% increase compared to fourth-quarter 2021 excluding the impact of Avive revenue in 202.

Period: fourth quarter and full-year 2022
Revenue: approximately $36.1 million, a 16% increase compared to fourth-quarter 2021 excluding the impact of Avive revenue in 202
Result: preliminary results

Exact text from the filing

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022

View on SEC.gov

Browse all earnings releases →

Axogen, Inc. filing history →

Source: SEC EDGAR

accession 0000805928-23-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.